Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-2.11%
$238.46
0% positive prob.
5-Day Prediction
-6.43%
$227.95
0% positive prob.
20-Day Prediction
-4.35%
$233.01
0% positive prob.
SEC 8-K filings with transcript text
Feb 12, 2026 · 100% conf.
1D
-2.11%
$238.46
5D
-6.43%
$227.95
20D
-4.35%
$233.01
wst-202602120000105770false00001057702026-02-122026-02-12
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) – February 12, 2026
(Exact name of registrant as specified in its charter)
Pennsylvania 1-8036 23-1210010
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
530 Herman O. West Drive, Exton, PA 19341-1147
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: 610-594-2900 Not Applicable
(Former name or address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading SymbolName of each exchange on which registered Common Stock, par value $0.25 per shareWSTNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1
Item 2.02 Results of Operations and Financial Condition. On February 12, 2026, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing its fourth-quarter and full year 2025 financial results. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. Item 7.01 Regulation FD Disclosure. The information set forth in “Item 2.02 Results of Operations and Financial Condition,” including the exhibit referred to therein, is incorporated herein by reference. A copy of the Company’s presentation materials used during the call will be available through the Investors link at the Company’s website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.2 and incorporated herein by reference. The information in this report (including the exhibits attached hereto) is being furnished pursuant to Item 2.02 and Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing. Item 9.01 Financial Statements and Exhibits.
(d) Exhibit No. Description
99.1 West Pharmaceutical Services, Inc. Press Release, dated February 12, 2026.
99.2 West Pharmaceutical Services, Inc. Presentation, dated February 12, 2026.
104 The cover page from the Company’s Current Report on Form 8-K, dated February 12, 2026, formatted in Inline XBRL.
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
/s/ Robert W. McMahon
Robert W. McMahon Senior Vice President, Chief Financial Officer
February 12, 2026
3
Exhibit No. Description
99.1 West Pharmaceutical Services, Inc. Press Release, dated February 12, 2026.
99.2 West Pharmaceutical Services, Inc. Presentation, dated February 12, 2026.
104 The cover page from the Company’s Current Report on Form 8-K, dated February 12, 2026, formatted in Inline XBRL.
4
Oct 23, 2025
wst-202510230000105770false00001057702025-10-232025-10-23
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) – October 23, 2025
(Exact name of registrant as specified in its charter)
Pennsylvania 1-8036 23-1210010
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
530 Herman O. West Drive, Exton, PA 19341-1147
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: 610-594-2900 Not Applicable
(Former name or address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading SymbolName of each exchange on which registered Common Stock, par value $0.25 per shareWSTNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1
Item 2.02 Results of Operations and Financial Condition. On October 23, 2025, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing its third-quarter 2025 financial results. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. Item 7.01 Regulation FD Disclosure. The information set forth in “Item 2.02 Results of Operations and Financial Condition,” including the exhibit referred to therein, is incorporated herein by reference. A copy of the Company’s presentation materials used during the call will be available through the Investors link at the Company’s website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.2 and incorporated herein by reference. The information in this report (including the exhibits attached hereto) is being furnished pursuant to Item 2.02 and Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing. Item 9.01 Financial Statements and Exhibits.
(d) Exhibit No. Description
99.1 West Pharmaceutical Services, Inc. Press Release, dated October 23, 2025.
99.2 West Pharmaceutical Services, Inc. Presentation, dated October 23, 2025.
104 The cover page from the Company’s Current Report on Form 8-K, dated October 23, 2025, formatted in Inline XBRL.
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
/s/ Robert W. McMahon
Robert W. McMahon Senior Vice President, Chief Financial Officer
October 23, 2025
3
Exhibit No. Description
99.1 West Pharmaceutical Services, Inc. Press Release, dated October 23, 2025.
99.2 West Pharmaceutical Services, Inc. Presentation, dated October 23, 2025.
104 The cover page from the Company’s Current Report on Form 8-K, dated October 23, 2025, formatted in Inline XBRL.
4
Jul 24, 2025
wst-202507240000105770false00001057702025-07-242025-07-24
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) – July 24, 2025
(Exact name of registrant as specified in its charter)
Pennsylvania 1-8036 23-1210010
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
530 Herman O. West Drive, Exton, PA 19341-1147
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: 610-594-2900 Not Applicable
(Former name or address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading SymbolName of each exchange on which registered Common Stock, par value $0.25 per shareWSTNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1
Item 2.02 Results of Operations and Financial Condition.
On July 24, 2025, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing its second-quarter 2025 financial results. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
The information set forth in “Item 2.02 Results of Operations and Financial Condition,” including the exhibit referred to therein, is incorporated herein by reference.
A copy of the Company’s presentation materials used during the call will be available through the Investors link at the Company’s website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.2 and incorporated herein by reference.
The information in this report (including the exhibits attached hereto) is being furnished pursuant to Item 2.02 and Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibit No. Description
99.1 West Pharmaceutical Services, Inc. Press Release, dated July 24, 2025.
99.2 West Pharmaceutical Services, Inc. Presentation, dated July 24, 2025.
104 The cover page from the Company’s Current Report on Form 8-K, dated July 24, 2025, formatted in Inline XBRL.
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
/s/ Bernard J. Birkett
Bernard J. Birkett Senior Vice President, Chief Financial Officer
July 24, 2025
3
Exhibit No. Description
99.1 West Pharmaceutical Services, Inc. Press Release, dated July 24, 2025.
99.2 West Pharmaceutical Services, Inc. Presentation, dated July 24, 2025.
104 The cover page from the Company’s Current Report on Form 8-K, dated July 24, 2025, formatted in Inline XBRL.
4
This page provides West Pharmaceutical Services Inc. (WST) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on WST's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.